Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment

 

 Permissions and Reprints

Summary

The level of platelet aggregation, measured with light transmission aggregometry (LTA) in platelet rich plasma (PRP), has been shown to predict outcomes after percutaneous coronary intervention (PCI). However, measuring parameters of platelet function with LTA is time consuming and weakly standardized. Thus, a fast and standardized method to assess platelet function after clopidogrel treatment would be of great value for clinical practice. A new method, multiple electrode platelet aggregometry (MEA), to rapidly measure platelet aggregation in whole blood has recently been developed. The aim of this study was to assess parameters of platelet function with MEA and LTA before and after administration of 600 mg clopidogrel. Blood samples from 149 patients scheduled for coronary angiography were taken after clopidogrel treatment; in addition, in 60 of the patients samples were available before clopidogrel treatment. ADP-induced platelet aggregation was measured with LTA and simultaneously in whole blood with MEA on the Multiplate analyzer. Platelet aggregation measured with MEA decreased significantly after clopidogrel treatment (P<0.0001). ADP-induced platelet aggregation assessed with MEA and LTA correlated significantly (Spearman rank correlation coefficient=0.71; P<0.0001).The results of MEA, a fast and standardized method to assess the platelet response to ADP prior to and after clopidogrel treatment, correlate well with LTA.

• References

• 1 Smith Jr. SC, Feldman TE, Hirshfeld Jr. JW. et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-286.
  CrossrefPubMedGoogle Scholar
• 2 Steinhubl SR, Charnigo R. Clopidogrel treatment prior to percutaneous coronary intervention: when enough isn't enough. JAMA 2006; 295: 1581-1582.
  CrossrefPubMedGoogle Scholar
• 3 Serebruany VL, Steinhubl SR, Berger PB. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
  CrossrefPubMedGoogle Scholar
• 4 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-1516.
  CrossrefPubMedGoogle Scholar
• 5 O’Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?. Circulation 2006; 114: e600-606.
  CrossrefPubMedGoogle Scholar
• 6 Buonamici P, Marcucci R, Migliorini A. et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
  CrossrefPubMedGoogle Scholar
• 7 Hochholzer W, Trenk D, Bestehorn HP. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
  CrossrefPubMedGoogle Scholar
• 8 Geisler T, Langer H, Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.
  CrossrefPubMedGoogle Scholar
• 9 Born GV, Cross MJ. Effect of adenosine diphosphate on the concentration of platelets in circulating blood. Nature 1963; 197: 974-976.
  CrossrefPubMedGoogle Scholar
• 10 Thebault JJ, Kieffer G, Lowe GD. et al. Repeateddose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost 1999; (Suppl. 25) 2: 9-14.
  PubMedGoogle Scholar
• 11 Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events?. J Am Coll Cardiol 2003; 41: 966-968.
  CrossrefPubMedGoogle Scholar
• 12 Michelson AD, Frelinger AL, 3rd Furman MI. Current options in platelet function testing. Am J Cardiol 2006; 98: 4N-10N.
  PubMedGoogle Scholar
• 13 Ivandic BT, Schlick P, Staritz P. et al. Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. Clin Chem 2006; 52: 383-388.
  CrossrefPubMedGoogle Scholar
• 14 von Beckerath N, Pogatsa-Murray G, Wieczorek A. et al. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 2006; 95: 910-911.
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Gurbel PA, Bliden KP, Etherington A. et al. Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 2007; 121: 107-115.
  CrossrefPubMedGoogle Scholar
• 16 van Werkum JW, van der Stelt CA, Seesing TH. et al. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006; 4: 2516-2518.
  CrossrefPubMedGoogle Scholar
• 17 Pampuch A, Cerletti C, de Gaetano G. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost 2006; 96: 767-773.
  Article in Thieme ConnectPubMedGoogle Scholar
• 18 Toth O, Calatzis A, Penz S. et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3: 135-158.
  CrossrefPubMedGoogle Scholar
• 20 Seyfert UT, Haubelt H, Vogt A. et al. Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18: 199-206.
  CrossrefPubMedGoogle Scholar
• 21 Penz SM, Reininger AJ, Toth O. et al. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thromb Haemost 2007; 97: 435-443.
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Mueller T, Dieplinger B, Poelz W. et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate(R) analyzer-comparison with two flow cytometric methods. Thromb Res. 2007 [Epub ahead of print].
  PubMedGoogle Scholar
• 23 Dynabyte Informationssysteme GmbH, Homepage (Accessed May 12, 2007, at www.multiplate.net
  PubMed
• 24 Gurbel PA, Bliden KP, Samara W. et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832.
  CrossrefPubMedGoogle Scholar
• 25 Müller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-787.
  Article in Thieme ConnectPubMedGoogle Scholar
• 26 Thebault JJ, Kieffer G, Cariou R. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost 1999; (Suppl. 25) 2: 3-8.
  PubMedGoogle Scholar
• 27 Samara WM, Bliden KP, Tantry US. et al. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 2005; 115: 89-94.
  CrossrefPubMedGoogle Scholar
• 28 Hochholzer W, Trenk D, Frundi D. et al. Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel. Thromb Res 2007; 119: 285-291.
  CrossrefPubMedGoogle Scholar
• 29 Wallen NH, Ladjevardi M, Albert J. et al. Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin. Thromb Res 1997; 87: 151-157.
  CrossrefPubMedGoogle Scholar
• 30 Labarthe B, Theroux P, Angioi M. et al. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005; 46: 638-645.
  CrossrefPubMedGoogle Scholar
• 31 Packham MA, Bryant NL, Guccione MA. et al. Effect of the concentration of Ca2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost 1989; 62: 968-976.
  Article in Thieme ConnectPubMedGoogle Scholar
• 32 Packham MA, Kinlough-Rathbone RL, Mustard JF. Thromboxane A2 causes feedback amplification involving extensive thromboxane A2 formation on close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987; 70: 647-651.
  PubMedGoogle Scholar
• 33 Weber A, Hohlfeld T, Schrör K. ADP-induced second wave aggregation in platelet rich plasma from hypercholesterolemic rabbits. Thromb Res 1991; 64: 703-712.
  CrossrefPubMedGoogle Scholar
• 34 Chrono-log Corporation, Homepage (Accessed September 15, 2007, at http://www.chronolog.com/disprb.htm
  PubMed
• 35 Bouchard BA, Tracy PB. Platelets, leukocytes, and coagulation. Curr Opin Hematol 2001; 8: 263-269.
  CrossrefPubMedGoogle Scholar